Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group

Trial Phase

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

Annals of the Rheumatic Diseases ◽

10.1136/ard.2010.134254 ◽

2010 ◽

Vol 70 (5) ◽

pp. 747-754 ◽

Cited By ~ 314

Author(s):

P. Quartier ◽

F. Allantaz ◽

R. Cimaz ◽

P. Pillet ◽

C. Messiaen ◽

...

Keyword(s):

Juvenile Idiopathic Arthritis ◽

Receptor Antagonist ◽

Controlled Trial ◽

Interleukin 1 ◽

Double Blind ◽

Double Blind Placebo ◽

Systemic Onset

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial

Arthritis & Rheumatism ◽

10.1002/art.10141 ◽

2002 ◽

Vol 46 (3) ◽

pp. 614-624 ◽

Cited By ~ 403

Author(s):

Stanley Cohen ◽

Eric Hurd ◽

John Cush ◽

Michael Schiff ◽

Michael E. Weinblatt ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Receptor Antagonist ◽

Controlled Trial ◽

Interleukin 1 ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718303450.793491945 ◽

2014 ◽

Author(s):

Timothy Beukelman

Keyword(s):

Juvenile Idiopathic Arthritis ◽

Receptor Antagonist ◽

Controlled Trial ◽

Interleukin 1 ◽

Double Blind ◽

Double Blind Placebo ◽

Systemic Onset

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial

Arthritis & Rheumatism ◽

10.1002/art.10578 ◽

2002 ◽

Vol 46 (11) ◽

pp. 2838-2846 ◽

Cited By ~ 136

Author(s):

George Nuki ◽

Barry Bresnihan ◽

Moraye B. Bear ◽

Dorothy McCabe ◽

Keyword(s):

Rheumatoid Arthritis ◽

Receptor Antagonist ◽

Clinical Improvement ◽

Controlled Trial ◽

Interleukin 1 ◽

Extension Phase ◽

Double Blind ◽

Double Blind Placebo ◽

The Orthokin® trial: a prospective double blind placebo-controlled randomised trial to investigate the effectiveness of autologous interleukin-1 receptor antagonist in the treatment of osteoarthritis (OA)

http://isrctn.org/> ◽

10.1186/isrctn44912979 ◽

2012 ◽

Author(s):

N.J.H. Raijmakers

Keyword(s):

Receptor Antagonist ◽

Interleukin 1 ◽

Randomised Trial ◽

Double Blind ◽

Double Blind Placebo ◽

A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

Annals of the Rheumatic Diseases ◽

10.1136/ard.2003.016014 ◽

2004 ◽

Vol 63 (9) ◽

pp. 1062-1068 ◽

Cited By ~ 189

Author(s):

S B Cohen

Keyword(s):

Rheumatoid Arthritis ◽

Receptor Antagonist ◽

Controlled Trial ◽

Interleukin 1 ◽

Double Blind ◽

Patient‐Reported Outcomes and the Association With Clinical Response in Patients With Active Psoriatic Arthritis Treated With Golimumab: Findings Through 2 Years of a Phase III, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial

Arthritis Care & Research ◽

10.1002/acr.22044 ◽

2013 ◽

Vol 65 (10) ◽

pp. 1666-1673 ◽

Cited By ~ 16

Author(s):

Arthur Kavanaugh ◽

Iain B. McInnes ◽

Gerald G. Krueger ◽

Dafna Gladman ◽

Anna Beutler ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Clinical Response ◽

Patient Reported Outcomes ◽

Controlled Trial ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Patient Reported

Faculty Opinions recommendation of Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734268130.793576219 ◽

2020 ◽

Author(s):

Pedro Machado

Keyword(s):

Tumor Necrosis ◽

Axial Spondyloarthritis ◽

Controlled Trial ◽

Phase Iii ◽

Inadequate Response ◽

Tumor Necrosis Factor Inhibitors ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Necrosis Factor

A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia

European Journal of Pain ◽

10.1016/j.ejpain.2010.09.013 ◽

2011 ◽

Vol 15 (5) ◽

pp. 509-514 ◽

Cited By ~ 24

Author(s):

Pascale Vergne-Sallel ◽

Carine Dufauret-Lombardl ◽

Christine Bonnetl ◽

Anne Simonl ◽

Richard Trèvesl ◽

...

Keyword(s):

Receptor Antagonist ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of genant and larsen scores

Arthritis & Rheumatism ◽

10.1002/1529-0131(200005)43:5<1001::aid-anr7>3.0.co;2-p ◽

2000 ◽

Vol 43 (5) ◽

pp. 1001 ◽

Cited By ~ 252

Author(s):

Yebin Jiang ◽

Harry K. Genant ◽

Iain Watt ◽

Mark Cobby ◽

Barry Bresnihan ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Receptor Antagonist ◽

Interleukin 1 ◽

Controlled Study ◽

Double Blind ◽

Dose Ranging ◽

Radiologic Progression